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Abstract Annexin-I (ANX-I) is a 37-kDa protein with a
calcium-dependent phospholipid-binding property. Previously
we have observed the inhibition of cytosolic phospholipase A2
(cPLA2) by ANX-I in the studies using purified recombinant
ANX-I, and proposed a specific interaction model for the
mechanism of cPLA2 inhibition by ANX-I [Kim et al. (1994)
FEBS Lett. 343, 251^255]. Here we have studied the role of
ANX-I in the cPLA2 signaling pathway by transient transfection
assay. The stimulation of Rat2 fibroblast cells with phorbol 12-
myristate 13-acetate (PMA) induced the c-fos serum response
element (SRE). The SRE stimulation by PMA was dramatically
reduced by (1) pretreatment with a cPLA2-specific inhibitor,
arachidonyltrifluoromethyl ketone, or (2) co-transfection with
antisense cPLA2 oligonucleotide, indicating that the SRE
activation was through cPLA2 activation. Co-transfection with
an ANX-I expression vector also reduced the SRE stimulation by
PMA, suggesting the inhibition of cPLA2 by ANX-I. The active
domain of ANX-I was mapped using various deletion mutants.
ANX-I(1^113) and ANX-I(34^346) were fully active, whereas
ANX-I(114^346) abolished the activity. Therefore the activity
was in the amino acid 34 to 113 region, which corresponds to the
conserved domain I of ANX-I. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Annexins (also called lipocortins) are structurally related,
calcium-dependent phospholipid-binding proteins that have
been implicated in various physiological roles including anti-
in£ammation, cell growth and di¡erentiation, adhesion and
membrane fusion [1^4]. Annexin-I (ANX-I), a 37-kDa mem-
ber of the annexin family of proteins, has been shown to
mediate anti-in£ammatory actions of glucocorticoids. The
anti-in£ammatory property has been proposed to be related
to the ability of ANX-I to inhibit phospholipase A2 (PLA2)
activity [5]. ANX-I has also been proposed to play regulatory
roles in the mitogenic signal transduction [6^8]. However, the
mechanism by which ANX-I plays a regulatory role in the
mitogenic signal transduction remains to be determined.
PLA2 represents a growing family of enzymes that have
been proposed to play roles in in£ammation, cytotoxicity
and mitogenesis [9,10]. The mammalian PLA2 family includes
at least three types of PLA2s, secretory PLA2 (sPLA2), cyto-
solic PLA2 (cPLA2) and Ca2-independent PLA2 (iPLA2).
Increasing reports suggest that cPLA2, an ubiquitously dis-
tributed 85^100-kDa protein, is a key enzyme responsible for
agonist-induced arachidonic acid release [9]. The activity of
cPLA2 is upregulated by an increase in intracellular Ca2
concentration and by protein kinase-catalyzed phosphoryla-
tion [11]. Enzymatic studies have shown that ANX-I inhibits
cPLA2 by speci¢c interaction with cPLA2 [12]. Suppression of
cPLA2 activity by ANX-I has also been shown in cultured
cells [13]. These results suggest that ANX-I may function as
an endogenous negative regulator of cPLA2. Thus, inhibition
of cPLA2 by ANX-I may constitute a plausible mechanism
for the regulation of mitogenic signal transduction by ANX-I.
The serum response element (SRE) in the c-fos promoter
has been shown to be necessary and su⁄cient for rapid in-
duction of the c-fos gene by serum or TPA [14]. SRE is a
primary nuclear target for many diverse signals including
growth factors, cytokines, and stresses. In order to investigate
whether ANX-I regulates signaling pathways controlled by
cPLA2, the e¡ect of ANX-I on the signaling pathways leading
to the activation of c-fos SRE by phorbol 12-myristate 13-
acetate (PMA) was analyzed. In this contribution, we show
that ANX-I attenuates PMA-induced c-fos SRE activation by
suppressing the activation of cPLA2.
2. Materials and methods
2.1. Chemicals and reagents
PMA, lysophosphatidic acid (LPA), hydrogen peroxide and mepa-
crine were purchased from Sigma (St. Louis, MO, USA). Arachidon-
yltri£uoromethyl ketone (AACOCF3) was from BioMol (Plymouth
Meeting, PA, USA). Fetal bovine serum (FBS), gentamicin, modi¢ed
Eagle’s medium, non-essential amino acids solution, Dulbecco’s modi-
¢ed Eagle’s medium (DMEM) and geneticin were from Gibco-BRL
(Gaithersburg, MD, USA). Monoclonal antibody to ANX-I was pur-
chased from Transduction Laboratories (Lexington, KY, USA). Anti-
sense oligonucleotide (GsTsGCTGGTAAGGATCTsAsT), of which
two linkages were phosphorothioated at both 5P and 3P ends, was
directed against codons 4^9 of the human cPLA2. A scrambled se-
quence oligonucleotide (GsTsGCTCCAAGTTTCTsAsT) was de-
signed and used for control. Both oligonucleotides were purchased
from Biobasic Co. (Ontario, Canada).
2.2. Plasmid preparation
The reporter plasmid pSRE-Luc has been described previously (Fig.
1A) [15]. The SRE oligonucleotide (23mer) is inserted at 353 of the
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truncated c-fos promoter fused to the luciferase gene. The ANX-I
cDNA (346 amino acids) fragment was cloned into BamHI/NotI sites
of pcDNA3 (Invitrogen, Groningen, the Netherlands) to construct
pANX. The deletion mutants of the ANX-I expression plasmid,
pANX(1^114), pANX(1^195), pANX(1^273), pANX(1^311), pANX-
(33^346) and pANX-I(114^346), were constructed by generating the
deletion DNA fragment by polymerase chain reaction and cloning
into pcDNA3 (Fig. 1B). All the ANX-I mutant clones were veri¢ed
by nucleotide sequence analysis.
2.3. Cell culture, DNA transfection and luciferase assay
Rat2 ¢broblast cells (ATCC, CRL 1764) were grown in DMEM
supplemented with 2 mM glutamine, non-essential amino acids solu-
tion and 10% FBS at 37‡C in a humidi¢ed atmosphere of 95% air and
5% CO2. For analysis by transient transfection, cells (1U105) were
seeded on 35-mm dishes and cultivated for 24 h. The cells were trans-
fected with 1.8 Wg of DNA/dish using Lipofectamine plus (Gibco-
BRL, Gaithersburg, MD, USA) according to the manufacturer’s in-
structions. The 1.8 Wg of DNA was made up from 0.6 Wg of reporter
plasmid (pSRE-Luc), 0.6 Wg of internal control (pCMV-LGAL) and
0.6 Wg of sample (pANX) or control (pcDNA3). The transfection was
stopped after 3 h by changing the culture medium to 0.5% FBS. After
36 h incubation, cells were lysed in 0.15 ml of lysis bu¡er (8 mM
Tricine, pH 7.8, 10 mM NaCl, 0.4 mM EDTA, 1 mM DTT, 0.2%
Triton X-100). The lysates were centrifuged and the supernatants were
used for the luciferase assay. The luciferase activity was measured
with the luciferase assay kit (Promega, Madison, WI, USA) as indi-
cated by the manufacturer. L-Galactosidase activity was measured
spectrophotometrically by the generation of o-nitrophenol from o-ni-
trophenyl-L-D-galactopyranoside, and was used as an internal stan-
dard to normalize the luciferase activity.
Stable Rat2 ¢broblast cell lines expressing ANX-I were established
by using pANX. Rat2 cells were transfected with pANX and clones
expressing ANX-I were selected by cultivating the cells in the presence
of geneticin (400 Wg/ml) for 3^4 weeks. The expression of ANX-I in
the clones was con¢rmed by Western blot analysis using anti-ANX-I
antibody.
2.4. Western blot analysis
The cells were lysed in the lysis bu¡er (20 mM Tris/HCl, pH 7.4,
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
sodium dodecyl sulfate (SDS), 1 mM phenylmethylsulfonyl£uoride,
5 mM benzamidine) and were disrupted by sonication (3U20 s).
The lysates were centrifuged for 10 min at 4‡C to remove debris,
and the protein concentrations were determined using the protein
assay kit (Bio-Rad, Richmond, CA, USA). Equivalent amounts of
samples (30 Wg of protein) were separated by SDS^polyacrylamide
gel electrophoresis, transferred to a nitrocellulose membrane and
probed with anti-ANX-I antibody.
2.5. Assay of cPLA2 activity
The cPLA2 activity was determined using 1-stearoyl-2-[1-14C]-
arachidonyl-sn-glycero-3-phosphocholine as the substrate, as de-
scribed previously [12].
3. Results
3.1. Inhibition of PMA-induced c-fos SRE activation by ANX-I
Regulatory role of ANX-I in the signaling pathway leading
to c-fos SRE activation was investigated by using the trans-
fection reporter assay. Rat2 ¢broblast cells were co-trans-
fected with the pSRE-Luc, the luciferase reporter (Fig. 1A)
and pCMV-GAL, which was used as an internal control. The
cells were serum-starved in DMEM containing 0.5% FBS for
36 h and then treated with PMA or 0.05% DMSO (vehicle).
To determine the optimum conditions for PMA-induced SRE
activation the cells were cultured under various PMA concen-
trations. As shown in Fig. 2A,B, SRE was maximally acti-
vated at 5^10 ng/ml PMA and 2 h after addition of PMA.
Therefore, all experiments were performed under these con-
ditions. E¡ects of ANX-I on the PMA-induced SRE activa-
tion were determined by co-transfection assay. Rat2 ¢broblast
cells were co-transfected with pSRE-Luc, pCMV-GAL and
pANX, the expression vector for human ANX-I (Fig. 1B).
The luciferase assay showed that ANX-I inhibited PMA-in-
duced SRE activation, whereas ANX-I had no e¡ect on LPA-
induced SRE activation (Fig. 3A). When a variable amount of
pANX is used, the inhibition of PMA-induced SRE activation
decreased with a decreasing amount of pANX (Fig. 3B).
3.2. cPLA2 activity is necessary for SRE activation induced by
PMA
While LPA signaling to c-fos SRE activation occurs primar-
ily through a Rho-PLA2 cascade, epidermal growth factor
signaling to the SRE activation can occur through a Rac-
PLA2 cascade [15,16]. Signaling pathways leading to SRE
activation by PMA, however, remain unknown.
To investigate whether PLA2 is involved in the activation
of SRE by PMA in Rat2 cells, the e¡ect of PLA2 inhibitors
on the PMA-induced SRE activation was examined. Both
mepacrine and AACOCF3 inhibited the PMA-induced SRE
activation (Fig. 4A). Inhibition by mepacrine, which inhibits
both cPLA2 and sPLA2, had a stronger e¡ect than
AACOCF3, a speci¢c cPLA2 inhibitor. The treatment of
Rat2 cells with AACOCF3 inhibited the PMA-induced SRE
activation to the level observed in the unstimulated cells, while
the inhibitor alone had little e¡ect on the expression of the
SRE reporter. On the other hand, mepacrine inhibited the
SRE reporter both in PMA-stimulated and -unstimulated
cells. These results show that cPLA2 activity is necessary for
the PMA-induced SRE activation and that PLA2s other than
cPLA2 may be involved in maintaining the basal level of SRE
activity. To con¢rm further that cPLA2 is involved in the
PMA-induced SRE activation, the e¡ect of antisense oligonu-
cleotide for cPLA2 on the SRE activity was examined. Fig.
5A reveals that 100 nM (0.6 Wg) antisense oligonucleotide
suppressed almost completely the PMA-induced SRE activa-
tion to the level of control cells while scrambled oligonucleo-
Fig. 1. Schematic presentation of plasmids used in this study. A:
The c-fos SRE reporter plasmid. The SRE oligonucleotide (23mer)
is inserted at 353 of the truncated c-fos promoter fused to the lucif-
erase gene [15]. B: ANX-I and the deletion mutants expression vec-
tors. Roman numerals represent the conserved repeat domains [1].
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tide had little e¡ect on the SRE activity. The antisense oligo-
nucleotide had no e¡ect on LPA-induced SRE activation.
These results further indicate that PMA-induced SRE activa-
tion is mediated by cPLA2.
3.3. Inhibition of PMA-induced SRE activation by ANX-I is
mediated by suppressing cPLA2
Results shown in Figs. 3^5 demonstrate that ANX-I inhib-
its cPLA2-mediated SRE activation. The inhibition by ANX-I
was investigated using stable Rat2 cells expressing ANX-I
(Rat2/ANX-I). Because the expression level of ANX-I was
very low in Rat2 cells as determined by Western blot analysis
(Fig. 6A), Rat2/ANX-I is a suitable model system to study the
gain of function by ANX-I. In the stable Rat2/ANX-I cells,
SRE activation was not induced by PMA, whereas SRE was
activated by LPA, which occurs through cPLA2-independent
pathways (Fig. 6B). To determine whether the attenuation of
PMA-induced SRE activation in stable Rat2/ANX-I cells is
ascribed to the suppression of cPLA2 by ANX-I, cPLA2 ac-
tivity was determined. The cPLA2 activity in Rat2/ANX-I
cells was much lower than in Rat2 cells in both PMA-unstim-
ulated and -stimulated cells (Fig. 6C).
3.4. Domain I in ANX-I is responsible for the inhibition of
PMA-induced SRE activation
The structure of ANX-I comprises a 43-amino acid-long
N-terminal and four conserved repeat domains of about 70
amino acids each as schematically shown in Fig. 1 [1]. To
determine which domain is responsible for the inhibition of
Fig. 2. Activation of c-fos SRE by PMA. Rat2 ¢broblast cells were
transfected with 1.8 Wg DNA (0.6 Wg pSRE-Luc, 0.6 Wg pCMV-
LGAL and 0.6 Wg pcDNA3) as described in Section 2. The cells
were serum-starved in DMEM containing 0.5% FBS for 36 h and
then treated with PMA or 0.05% DMSO (vehicle). A: Cells were
cultured in the presence of 2.5^100 ng/ml PMA for 2 h. B: Cells
were cultured in the presence of 10 ng/ml PMA for 0^6 h. Lucifer-
ase activity was normalized with L-galactosidase activity. Data
shown are the averages of triplicate values.
Fig. 3. Inhibition of PMA-induced c-fos SRE activation by ANX-I.
A: Cells were transfected with 1.8 Wg of DNA (0.6 Wg pSRE-Luc,
0.6 Wg pCMV-LGAL, and 0.6 Wg pANX or 0.6 Wg of pcDNA3) and
cultured in the presence of 10 ng/ml PMA or 10 WM LPA for 2 h.
B: Cells were transfected with 1.2 Wg of the reporter DNA (0.6 Wg
of pSRE-Luc and 0.6 Wg of pCMV-LGAL) and a variable amount
of pANX. CV, control vector (pcDNA3); ANX-I, pANX. Data
shown are the averages of triplicate values and are representative of
at least three independent experiments.
Fig. 4. Inhibition of PMA-induced SRE activation by PLA2 inhibi-
tors. After 36 h serum starvation, cells were treated with 1 WM me-
pacrine and/or 10 WM AACOCF3 for 30 min, followed by treatment
with 10 ng/ml PMA for 2 h. Other details were as in Figs. 2 and 3.
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PMA-induced SRE activation, various deletion mutants of
ANX-I were used (Fig. 1B). Transient transfection of these
mutants attenuated PMA-induced SRE activation. ANX-I C-
terminal deletion mutants ANX/1^273, ANX/1^195 and
ANX/1^113 attenuated PMA-induced SRE activation to the
comparable level of wild type ANX-I (Fig. 7). In the case of
deletion of N-terminal (ANX/33^346) or of C-terminal
RACK (receptor for activated C-kinase) binding sites
(ANX/1^322) [17], PMA-induced SRE activation was inhib-
ited to the basal level, which is lower than the full-length
ANX-I and other deletion mutants. These results suggest
that the N-terminal and C-terminal ends might be involved
in the positive regulation of the signaling pathway leading to
SRE activation by PMA. In fact, the C-terminal 13 peptide
has been shown to play a role in activating PKC [17,18]. On
the other hand, the deletion of the N-terminal and domain I
(ANX/114^346) abolished most of the inhibitory activity (15%
inhibition of PMA-induced SRE activation). Taken together,
these results showed that domain 1 of ANX-I is responsible
for the inhibitory action of PMA-induced SRE activation.
4. Discussion
In this contribution we have demonstrated that (1) cPLA2
is involved in the activation of c-fos SRE activation, (2) ANX-
I inhibits this process and (3) domain I (amino acids 34^143)
of ANX-I is responsible for this inhibition. In addition, we
provide evidence suggesting that PMA stimulates c-fos SRE
via cPLA2-dependent cascade. The signaling cascade by which
PMA causes stimulation of c-fos SRE remains to be deter-
mined. It has been shown that extracellular signal regulated
kinases (ERKs), including ERK1 and ERK2, also known as
p44mapk and p42mapk, are induced by PMA [11]. ERKs phos-
phorylate and regulate the activity of certain enzymes, includ-
ing cPLA2 and p90rsk, and nuclear proteins, such as the ter-
nary complex factor p62TCF or Elk-1 [11]. The latter
represents a critical event in controlling the expression of sev-
eral genes, including c-fos. Therefore, the potential pathway
involving ERKs-p62TCF/Elk-1 or ERKs-cPLA2/p90rsk-linked
Fig. 5. E¡ect of cPLA2 antisense oligonucleotide on the PMA-in-
duced SRE activation. An oligonucleotide with antisense cPLA2 se-
quence (GsTsGCTGGTAAGGATCTsAsT), of which two linkages
were phosphorothioated at both the 5P and 3P ends was directed
against codons 4^9 of the human cPLA2. Scrambled sequence oligo-
nucleotide (GsTsGCTCCAAGTTTCTsAsT) was used for the con-
trol. Rat2 cells were transfected with 1.8 Wg DNA (0.6 Wg pSRE-
Luc, 0.6 Wg pCMV-LGAL and 0.6 Wg oligonucleotide). Other details
were as in Figs. 2 and 3. AS, antisense oligonucleotide; SR,
scrambled oligonucleotide; CV, control vector.
Fig. 6. ANX-I inhibits PMA-induced SRE activation in stable Rat2/
ANX-I cells. Rat2 cells were transfected with pANX and clones ex-
pressing ANX-I were selected by cultivating the cells in the presence
of geneticin (400 Wg/ml) for 3^4 weeks. A: Western blot analysis us-
ing anti-ANX-I antibody. M, size marker; 1, puri¢ed ANX-I; 2,
Rat2 cells ; 3, Rat2/ANX-I cells. B: Inhibition of PMA-induced
SRE activation in Rat2/ANX-I cells. SRE activation was determined
as in Figs. 2 and 3. C: cPLA2 activity in Rat2 and Rat2/ANX-I
cells. cPLA2 activity was determined as described in Section 2.
Fig. 7. Inhibition of PMA-induced SRE activation by ANX-I dele-
tion mutants. Deletion mutants described in Fig. 1 were used. De-
tails are as in Figs. 2 and 3.
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cascades may possibly mediate the stimulation of c-fos SRE.
Our data provide an essential role of cPLA2 in PMA-signal-
ing to SRE (Figs. 4,2 and 5). In addition, we present a key
role of ANX-I in PMA-induced nuclear signaling. However,
the exact mechanism by which ANX-I regulates PMA-signal-
ing to SRE remains to be determined, although ANX-I is
known to regulate cPLA2 negatively. Because of a lack of
evidence for the direct interaction of ANX-I with cPLA2 in
cells, the hypothesis that ANX-I may be a speci¢c endogenous
inhibitor of cPLA2 has been controversial. Our previous in
vitro studies have shown that ANX-I interacts with cPLA2
[12]. The results shown in Figs. 6 and 7 support the hypoth-
esis. Whether inhibition by ANX-I is a major mechanism of
cPLA2 regulation or not needs further study.
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